Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine

Viral Immunology

Volumn 21, Issue 1, 2008, Pages 27-37

  Gai, Weiwei ^a,b   Zou, Wei ^b   Lei, Lei ^b   Luo, Junyi ^b   Tu, Haobo ^b   Zhang, Yan ^b   Wang, Kai ^b   Tien, Po ^b   Yan, Huimin ^a,b  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FECES; FEMALE; GENITAL SYSTEM; IMMUNIZATION; INTESTINE; LUNG; MONOTHERAPY; NONHUMAN; SALIVA; SEVERE ACUTE RESPIRATORY SYNDROME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; FEMALE; GENITALIA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; INTESTINAL MUCOSA; LUNG; MICE; NEUTRALIZATION TESTS; OLIGODEOXYRIBONUCLEOTIDES; SALIVA; SARS VIRUS; SERUM; VACCINES, INACTIVATED; VIRAL VACCINES;

SARS CORONAVIRUS;

EID: 41349095529     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2007.0079     Document Type: Article

References (36)

1. Burns JW, Siadat-Pajouh M, Krishnaney AA, and Greenberg HB: Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996;272:104-107.
2. Chen J, and Subbarao K: The immunobiology of SARS (*). Annu Rev Immunol 2007;25:443-472.
3. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, and Krieg AM: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998;160:870-876.
4. Freytag LC, and Clements JD: Mucosal adjuvants. Vaccine 2005;23:1804-1813.
5. Gallichan WS, and Rosenthal KL: Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995;13:1589-1595.
6. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, and Rosenthal KL: Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001;166:3451-3457.
7. Giroglou T, Cinatl J Jr., Rabenau H, Drosten C, Schwalbe H, Doerr HW, and von Laer D: Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol 2004;78:9007-9015.
8. Guan Y, Zheng BJ, He YQ, et al.: Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276-278.
9. Kang SM, and Compans RW: Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol 2003;77:3615-3623.
10. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, and Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
11. Lamm ME: Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 1997;51:311-340.
12. Lau YL, and Peiris JS: Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol 2005;17:404-410.
13. Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N, Yuen KY, and Sung JJ: Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 2003;125:1011-1017.
14. Li, P-p, Yang X-m, Fang Z-z, et al.: Preparation of inactivated SARS vaccine. Chin J Biologicals 2005;18:390-393.
15. Li W, Shi Z, Yu M, et al.: Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676-679.
16. Lin R-S: New models of the SARS epidemic, 2003. http://www.sarswatch.org/ comments.php?id=344_0_1_20_C.
17. Martina BE, Haagmans BL, Kuiken T, et al.: Virology: SARS virus infection of cats and ferrets. Nature 2003;425:915.
18. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, and Nedrud JG: Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A 1992;89:6901-6905.
19. Mazanec MB, Lamm ME, Lyn D, Portner A, and Nedrud JG: Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. Virus Res 1992;23:1-12.
20. McCluskie MJ, and Davis HL: Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 2000;19:413-422.
21. Michetti P, Mahan MJ, Slauch JM, Mekalanos JJ, and Neutra MR: Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect Immun 1992;60:1786-1792.
22. Nie Y, Wang G, Shi X, et al.: Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis 2004;190:1119-1126.
23. Ogra PL, Faden H, and Welliver RC: Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001;14:430-445.
24. Qu D, Zheng B, Yao X, et al.: Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 2005;23:924-931.
25. Subbarao K, McAuliffe J, Vogel L, et al.: Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004;78:3572-3577.
26. Takasuka N, Fujii H, Takahashi Y, et al.: A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 2004;16:1423-1430.
27. Tamura S, Funato H, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, and Kurata T: Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur J Immunol 1991;21:1337-1344.
28. Tang L, Zhu Q, Qin E, et al.: Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol 2004;23:391-394.
29. Taylor DR: Obstacles and advances in SARS vaccine development. Vaccine 2006;24:863-871.
30. ter Meulen J, Bakker AB, van den Brink EN, et al.: Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004;363:2139-2141.
31. To KF, and Lo AW: Exploring the pathogenesis of severe acute respiratory syndrome (SARS): The tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol 2004;203:740-743.
32. World Health Organization: Cumulative number of reported probable cases of SARS, 2003. http://www.who.int/csr/sars/country/2003_06_05/en/
33. Xinhua News Agency SARS vaccine trial runs smoothly to second stage, 2005. http://my.tdctrade.com/airnewse/ index.asp?id=8856.
34. Yamamoto S, Kiyono H, Yamamoto M, et al.: A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A 1997;94:5267-5272.
35. Yan H, Lamm ME, Bjorling E, and Huang YT: Multiple functions of immunoglobulin A in mucosal defense against viruses: An in vitro measles virus model. J Virol 2002;76:10972-10979.
36. Zhou J, Wang W, Zhong Q, et al.: Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 2005;23:3202-3209.